Dose-escalation study evaluating investigational medicine venetoclax in combination with an immunochemotherapy
regimen, bendamustine and rituximab, in patients with NHL
was followed by obinutuzumab maintenance therapy.
They describe strategies of passive and active immunotherapy, improving immunotherapeutic responses using combinations of agents for immunochemotherapy
, and targeting strategies to defeat immune suppression.
MatBA[R]-DLBCL assesses the presence of single biomarkers as well as genome complexity as measures of overall survival following front-line immunochemotherapy
Durable remission of large B-cell lymphoma transformed from lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia successfully treated with sequential immunochemotherapy
followed by reduced-intensity allogeneic stem cell transplantation.
Randomized, controlled study on adjuvant immunochemotherapy
with PSK in curatively resected colorectal cancer.
Histologic subtype of metastatic renal cell carcinoma predicts response to combined immunochemotherapy
with interleukin 2, interferon alpha and 5-fluorouracil.
HLA antigen as predictive index for the outcome of breast cancer patients with adjuvant immunochemotherapy
To date, the only treatment bearing curative potential is allogeneic stem cell transplantation; in contrast to conventional immunochemotherapy
, it can provide long-term disease control, even in patients with del Up or other unfavorable biological and clinical risk factors.
Supportive treatments, IVIG and sometimes immunochemotherapy
are the treatment options in IAHS (1,2).
with Rituximab Improves Overall Survival in Patients with Follicular and Mantle Cell Lymphoma: Updated Meta-Analysis Results.